✦ LIBER ✦

Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer

✍ Scribed by Anne S. Tsao; Diane Liu; J. Jack Lee; Margaret Spitz; Waun Ki Hong

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 253 KB
Volume: 106
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21884

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment outcome for patients with prim

Treatment outcome for patients with primary nonsmall-cell lung cancer and synchronous brain metastasis

✍ Mark A. Chidel; John H. Suh; John F. Greskovich; Patrick A. Kupelian; Gene H. Ba 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 2 views

The purpose of this study was to evaluate the outcome of treatment for patients with newly diagnosed nonsmall-cell lung cancer (NSCLC) with an isolated, single, synchronous brain metastasis. A retrospective review was performed evaluating any patient diagnosed between 1982 and 1996 at the Cleveland

Clinical factors affecting acquired resi

Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer

✍ Yoshihiko Segawa; Katsuyuki Hotta; Shigeki Umemura; Yoshiro Fujiwara; Tetsu Shin 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 1 views

Survival outcome and predictors of gefit

Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer

✍ Chih-Hsin Yang; Jin-Yuan Shih; Kun-Chieh Chen; Chong-Jen Yu; Tsung-Ying Yang; Ch 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB 👁 1 views

Prognostic model to predict outcomes in

Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment

✍ Min Jae Park; Jeeyun Lee; Jung Yong Hong; Moon Ki Choi; Joon Ho Yi; Su Jin Lee; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 437 KB 👁 1 views

## Abstract ## BACKGROUND: A prognostic model based on clinical parameters for nonsmall cell lung cancer (NSCLC) patients treated with gefitinib (250 mg/day) as a salvage therapy was devised. ## METHODS: Clinical data regarding a total of 316 metastatic or recurrent NSCLC patients who were treat

Phase 1 trial of everolimus and gefitini

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer

✍ Daniel T. Milton; Gregory J. Riely; Christopher G. Azzoli; Jorge E. Gomez; Rober 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 1 views

## Abstract ## BACKGROUND. Preclinical studies have demonstrated that the inhibition of the PI3K/Akt/mTOR pathway restores gefitinib sensitivity in resistant cancer cell lines. A phase 1 study was conducted of the combination of everolimus, an mTOR inhibitor, and gefitinib to determine a daily dos

Extent of lymphadenectomy and outcome fo

Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer

✍ John M. Varlotto; Abram Recht; Margaret Nikolov; John C. Flickinger; Malcolm M. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 383 KB 👁 1 views